BGS closes year 2025 with a slight increase and expects stable growth in 2026
BGS closed fiscal year 2025 with a slight increase compared to the previous year. This was achieved by the radiation sterilization division, where revenue grew primarily due to orders from the medical technology sector. Radiation crosslinking, on the other hand, continued to show subdued growth. For 2026, BGS anticipates stable growth, supported by reliable demand from the medical technology sector.